Wyeth Consumer Healthcare launches new gender-, age-specific multivitamin line
MADISON, N.J. Wyeth Consumer Healthcare on Tuesday announced the availability of a new gender- and age-specific adult multivitamin line. Centrum Ultra Women’s and Men’s and Centrum Silver Ultra Women’s and Men’s are specially formulated, taking into account recommendations established by the Institute of Medicine along with the latest nutritional science, the company stated.
“Millions of Americans have relied on Centrum, the world’s leading adult multivitamin brand, for more than 30 years,” stated Paul Sturman, president Wyeth Consumer Healthcare. “We listen closely to the needs of our consumers and combine these insights with the latest nutritional advances. Centrum Ultra provides a new, scientifically advanced option to meet consumers’ growing demand for gender-and age-based multivitamins.”
Many Americans still find it difficult to get the recommended amounts of vitamins and minerals they need from food alone despite the wide variety of nutritional choices available. The 2005 U.S. Department of Agriculture Healthy Eating Index found that the U.S. population did not take in enough fruits, vegetables, whole grains and fat-free or low-fat milk and suggests that Americans can improve their diet by choosing more nutrient rich foods.
Centrum Ultra Women’s is specially formulated with key nutrients to help meet a woman’s nutritional needs. It includes vitamin D, which emerging science suggests supports breast health, and calcium for bone health; 500 mg of calcium, more than any leading women’s multivitamin brand; biotin, beta-carotene and vitamins A, C and E to help maintain healthy skin, hair and nails; B vitamins to help unlock energy; and antioxidants including selenium and zinc to help support immune function.
In addition to many of the vitamins and minerals listed above, Centrum Ultra Men’s contains vitamins B6, B12 and folic acid to help support heart health.
Centrum Silver Ultra Women’s, formulated for women ages 50 and older, contains lutein and vitamins A, C and E to help support healthy eyesight.
Time Inc. relaunches ALLYOU.com
NEW YORK Time Inc. relaunched ALLYOU.com Monday as a value destination designed to help women cut costs and “enjoy life for less.”
From the team that created Time Inc.’s ALL YOU magazine, geared to the value-driven woman, the new ALLYOU.com contains money-saving tips along with exclusive high-value coupons as part of an extensive coupon database, daily discount offers, low-cost recipes and more.
“Our goal at ALL YOU is to offer practical, affordable solutions that empower women to save money in every area of their lives,” stated executive editor Susan Spencer. “In addition to delivering value-focused editorial content from budget beauty ideas to meals under $2, the new site also allows us to share exclusive printable coupons, discount codes and up-to-the-minute deals. ALLYOU.com is the go-to destination for value-minded women.”
Advertisers committed to providing exclusive coupons for the launch of ALLYOU.com include: Church & Dwight, Enzymatic Therapy, Ghirardelli Chocolate Company, Novartis Consumer Healthcare and Snapple, among others.
ALL YOU magazine launched in September 2004 with a rate base of 500,000. It has grown steadily to its current 975,000 and will rise again to 1.02 million in January 2010, Time Inc. stated.
Time Inc.’s ALL YOU magazine is geared to the value-driven woman and sold on newsstands at Walmart stores nationwide and by subscription.
CDC: Third patient identified with Tamiflu-resistant H1N1 infection, will not change recommended treatment protocol
ATLANTA The Centers for Disease Control and Prevention last week confirmed that a third person was identified with a Tamiflu (oseltamivir) resistant novel H1N1 virus infection; however, the agency has not changed its recommended treatment protocol for the H1N1 influenza virus.
All three people have fully recovered after uncomplicated illnesses and did not have contact with each other. Two of the three people are reported to have developed illness while taking oseltamivir preventatively after an exposure to a close contact with novel influenza A (H1N1). The third person had no known exposure to oseltamivir.
Results from ongoing testing of novel influenza A (H1N1) viruses indicate that oseltamivir resistance remains rare, the CDC stated.
Judicious use of antiviral medications is recommended to reduce the possibilities of the development and spread of antiviral resistant influenza viruses.
Use of zanamivir or oseltamivir should be focused on treatment of persons with suspected novel H1N1 influenza who are hospitalized or at higher risk for complications due to influenza, even if hospitalization is not required.